| | Cover Image: mTOR colocalizes with the Golgi apparatus. Colocalization of mTOR and the Golgi apparatus in Human Vascular Smooth Muscle Cells (HVSMC). Wild type mTOR (Flag-mTOR/pBJ5) was overexpressed in HVSMC by electroporation. The localization of mTOR in HVSMCs was determined by immunofluorescent staining with an anti-mTOR antibody (red, Cell Signalling (#2972), Danvers, MA). Anti-Golgin-97 antibody was used to detect the Golgi apparatus (green, Molecular Probes (A-21270), Leiden, The Netherlands). Shown is an image captured by scanning confocal microscopy. The yellow color shows colocalization of mTOR with Golgi apparatus. DAPI was used for DNA staining (nuclear compartment). (Robert J. Wagner, Eva M. Rzucidlo, M.D.) GUEST EDITORS Richard J. Powell, Anton N. Sidawy, Michael T. Watkins Preface 1A Richard J. Powell, MD, Anton N. Sidawy, MD, and Michael T. Watkins, MD, Lebanon, NH; Washington, DC; and Boston, Mass Chapter 1  Reviving the vascular surgeon–scientist: An interim assessment of the jointly sponsored Lifeline Foundation/National Heart, Lung, and Blood Institute William J. von Liebig Mentored Clinical Scientist Development (K08) Program 2A Robert W. Thompson, MD, Beth Schucker, MS, K. Craig Kent, MD, Alexander W. Clowes, MD, Larry W. Kraiss, MD, John A. Mannick, MD, and James S. T. Yao, MD, St. Louis, Mo; Bethesda, Md; New York, NY; Seattle, Wash; Salt Lake City, Utah; Boston, Mass; and Chicago, Ill Chapter 2  Translational control in endothelial cells 8A Peter B. Brant-Zawadzki, MD, Douglas I. Schmid, MD, Huimao Jiang, MD, Andrew S. Weyrich, MD, Guy A. Zimmerman, MD, and Larry W. Kraiss, MD, Salt Lake City, Utah Chapter 3  Smooth muscle cell signal transduction: Implications of vascular biology for vascular surgeons 15A Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M. Pimiento, MD, Stephen P. Maloney, MD, Desarom Teso, MD, Jacek J. Paszkowiak, MD, Tormod S. Westvik, MD, Fabio A. Kudo, MD, PhD, Toshiya Nishibe, MD, PhD, and Alan Dardik, MD, PhD, New Haven, Waterbury, and West Haven, Conn; and Toyoake, Aichi, Japan Chapter 4  Regulation of vascular smooth muscle cell differentiation 25A Eva M. Rzucidlo, MD, Kathleen A. Martin, PhD, and Richard J. Powell, MD, Lebanon, NH Chapter 5  Integrin αvβ3 as a target in the prevention of neointimal hyperplasia 33A Taku Kokubo, MD, Hisashi Uchida, MD, and Eric T. Choi, MD, St. Louis, Mo Chapter 6  Angiogenesis and vasculogenesis: Inducing the growth of new blood vessels and wound healing by stimulation of bone marrow–derived progenitor cell mobilization and homing 39A Omaida C. Velazquez, MD, Philadelphia, Pa Chapter 7  The chemokine system in arteriogenesis and hind limb ischemia 48A Paula K. Shireman, MD, San Antonio, Tex Chapter 8  Clinical, cellular, and molecular aspects of arterial calcification 57A Raul J. Guzman, MD, Nashville, Tenn Chapter 9  The role of nitric oxide in the pathophysiology of intimal hyperplasia 64A Sadaf S. Ahanchi, MD, Nick D. Tsihlis, PhD, and Melina R. Kibbe, MD, Chicago, Ill Chapter 10  Molecular engineering of vein bypass grafts 74A Michael S. Conte, MD, Boston, Mass Chapter 11  Genomic and proteomic determinants of lower extremity revascularization failure: Rationale and study design 82A Peter R. Nelson, MD, Kerri A. O’Malley, PhD, Robert J. Feezor, MD, Lyle L. Moldawer, PhD, and James M. Seeger, MD, Gainesville, Fla Chapter 12  Cytokines and the early vein graft: Strategies to enhance durability 92A C. Keith Ozaki, MD, Gainesville, Fla Chapter 13  Tissue engineering applications to vascular bypass graft development: The use of adipose-derived stem cells 99A Paul DiMuzio, MD, and Thomas Tulenko, PhD, Philadelphia, Pa Chapter 14  Novel thromboresistant materials 104A Sumanas W. Jordan and Elliot L. Chaikof, MD, PhD, Atlanta, Ga Chapter 15  Molecular characterization of post-thrombotic syndrome 116A Lornie J. Phillips II, MD, and Rajabrata Sarkar, MD, PhD, San Francisco, Calif Chapter 16  Assessing the effectiveness of endografts: Clinical and experimental perspectives 123A Larisse K. Lee, MD, and Peter L. Faries, MD, New York, NY Chapter 17  Impact of outcomes research on the management of vascular surgery patients 131A John E. Rectenwald, MD, and Gilbert R. Upchurch, Jr, MD, Ann Arbor, Mich Chapter 18  Functional outcome of critical limb ischemia 141A Gregory J. Landry, MD, Portland, Ore Chapter 19  Percutaneous treatment of peripheral vascular disease: The role of diabetes and inflammation 149A Louis L. Nguyen, MD, MBA, MPH, Boston, Mass Chapter 20  Randomized clinical trials: How will results influence clinical practice in the management of symptomatic and asymptomatic extracranial carotid occlusive disease? 158A Robert W. Hobson II, MD, Newark, NJ PII: S0741-5214(07)00713-6 doi:10.1016/S0741-5214(07)00713-6 | |
|